HER2 Positive Breast Cancer

Erika P. Hamilton, MD, discusses the role of T-DXd in HER2+ and HER2-low breast cancer, the evolution of CDK4/6 inhibitors in HR+ disease, and how genetic testing supports precision medicine research. @ErikaHamilton9 @SarahCannonDocs #bcsm #OncLiveIPC https://t.co/KYnlhERuBx (@OncLive)

Terrific presentation on opportunities and unmet needs in HER2-positive breast cancer by @stolaney1 at #IBCEast. An expanding pipeline of anti-HER2 agents and the development of helpful biomarkers is allowing for a progressive increase in the tailoring of our treatments. (@PTarantinoMD)

Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer - @DrSGraff #oncodaily #oncology #CancerResearch #HER2 https://t.co/h22k90nufb (@oncodaily)

Now in ⁦@CBCjournal⁩: Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer, with ⁦@YAbdouMD⁩ and #FengtingYan I love the way the figures turned out—will share them over the coming days! #bcsm https://t.co/TNFnI1a4qI (@DrSGraff)

The formatted version of the ESMO Consensus Statements on HER2-low breast cancer is finally published – @PTarantinoMD #cancer #cancercare #breastcancer #cancersupport #esmo #oncology #oncodaily https://t.co/5cL9dbyqi8 (@oncodaily)

🚨Thrilled to share our latest article on treatment options of #HER2low #breastcancer & proposed treatment sequencing algorithm published in @AmericanCancer journal @JournalCancer. @gandhi_shipra @oreganruth @DhakalAjay @RoswellPark @RoswellHemOnc https://t.co/iSdSb8KvYx (@royaryam)

"We are now in a new era of HER2 breast cancer, particularly in the unresected, metastatic setting, that is no longer considered binary as positive or negative." @hoperugo @UCSFHospitals via @CancerTherAdvsr https://t.co/8sAEdjaEy9 (@UCSFCancer)

Congrats to ⁦@FAndreMD⁩ et al! ⚽️🥅 👉🏼Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial ⁦@TheLancet⁩ https://t.co/4Bu9eUfFA8 (@VivekSubbiah)

⭐️ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer ⁦@PTarantinoMD⁩ ⁦@curijoey⁩ ⁦@Annals_Oncology⁩ ⁦@myESMO⁩ https://t.co/alW4Ec5TS0 (@VivekSubbiah)

In this interview by @VJOncology I share a summary of the findings presented at #ASCO23 about the academic #NeoRhea trial - neoadjuvant palbociclib + ET for early ER+/HER2-neg #breastcancer https://t.co/2KtmdkZGmo (@ElisaAgostinett)

New 📰published in @Annals_Oncology on the association of #HER2DX with pathological complete response and survival outcomes in #HER2-positive #BreastCancer. @G_Villacampa @stolaney1 @EMittendorfMD @prat_aleix @adawaksmd @vitti10 @awolff @patri0608 @sltc21 https://t.co/6RBjvvkGmI (@DFCI_BreastOnc)

Q8: What are some promising areas of ongoing research in HER2-low breast cancer? #HER2low #PathTwitter, #BreastPath @feldmanm30 @Baskotacytopath @DrBuiPathology @drshiwei (@ASCP_Chicago)

A8: Newer antibody drug conjugates (ADCs) emerging; may be more effective in patients with HER2-low breast cancer #HER2low #PathTwitter #BreastPath (@DrShiWei)

Q7: What happens to HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer? #asco23 https://t.co/OpQKvhiQcB #HER2low #PathTwitter, #BreastPath @feldmanm30 @Baskotacytopath @DrBuiPathology @drshiwei (@ASCP_Chicago)

Here, Paolo Tarantino, MD, discusses discoveries made in the genomic characterizations and treatment of HER2-low, HER2-zero, and HER2-positive breast cancers, which he presented at the San Antonio Breast Cancer Symposium. https://t.co/Iie4Qc3BLM @DanaFarber @PTarantinoMD #SABCS (@OncLearnNetwork)

New in #npjBCancer, @FilipaLynce @IBC_DanaFarber demonstrated in a cohort study that patients with de novo HER2-positive metastatic inflammatory #BreastCancer have favorable outcomes and there may be a role for local therapy for these patients. https://t.co/u7Vn9CFvN5 (@Nature_NPJ)

Thanks to @Annals_Oncology for highlighting our ESMO Consensus statements on HER2-low breast cancer, where we provide guidance on the 20 most controversial topics in the field. Supported by @myESMO, which also developed the wonderful video abstract below! https://t.co/axbCPl4Qfy https://t.co/PdxrzNMeSj (@PTarantinoMD)

Topics if HER2-low breast cancer covered in this Expert Consensus Statement in Annals of Oncology: (i) biology; (ii) pathologic diagnosis; (iii) clinical management; (iv) clinical trial design . https://t.co/O3sAnASDus @PTarantinoMD @curijoey @FAndreMD @GPentheroudakis #bcsm (@Annals_Oncology)

📢Loss of HER2 in #breastcancer is more common than thought, occurring in up to 50% of cases. 👏https://t.co/xnXVPpHudN @PTarantinoMD @HashizumePedro @andrepcdc @EmaFer_90 @Ritalepp #HER2Loss #ResearchNeeded #TumorHeterogeneity (@cdrjournal)

.@RimmPathology explains how to better identify HER-2 Low #BreastCancer & how pathologists can better distinguish IHC 1+/2+ from 0. #pathology #CancerResearch @YaleMed @YaleCancer https://t.co/UH05YI460n (@yalepathology)

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial https://t.co/MbnePsmcDo #bcsm #breastcancer #oncology #ASCO23 @DrLisaCarey @UNC_Lineberger @JavierCortesMD (@ASCOPost)

Women are being reclassified from HER2-neg #breastcancer & getting life-changing care. “With >60% of patients being HER2-low, this is opening up a lot of treatment options.” @maryam_lustberg #ASCO23 https://t.co/hy0kSSdrVu @SmilowCancer @YaleMed @YNHH @YaleBreast (@YaleCancer)

How to navigate the emerging landscape of HER2-low #BreastCancer? Eagerly awaited, ESMO Expert Consensus statements aim to address major controversies stemming from recent research in the field 📌https://t.co/bDibfwIGpC @PTarantinoMD (@myESMO)

Recently published📰in @Nature_NPJ Breast by Dr. Ana Garrido-Castro and colleagues👉Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer #IBC https://t.co/W3HuMXNUgs @FilipaLynce @Merregan @RosenbluthLab @jenniferbellon2 @stolaney1 @nlinmd (@DFCI_BreastOnc)

Important to consider neuropathy risk in equally effective taxanes regimens for Her2 +ve #breastcancer #ASCO2023 (@fsalmasi)

Nan Chen, MD, Assistant Professor @UChicagoMed presents cool data on the outcomes from using combinatorial treatment of #Pembrolizumab and #Mifepristone in HER2-ve #breastcancer patients. @UCCancerCenter @UChicagoBreast @UChicagoHemOnc @RitaNandaMD (@UCCancerCenter)

Our consensus on HER2-low breast cancer is online. @myESMO @Annals_Oncology (@AnnetteLebeau)

Watch Drs. Schnitt (@SchnittStuart), Tarantino (@PTarantinoMD), and Reis-Filho demonstrate multidisciplinary collaboration to ensure appropriate #biomarker testing and treatment for patients with #HER2low #BreastCancer https://t.co/uYijoPaBy1 (@PeerView)

Ahead of #ASCO23, check out our review on the current landscape of HER2-positive metastatic breast cancer ➡️ @YAbdouMD @FengtingYan @CBCjournal #bcsm Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast ... https://t.co/BOKSV95ajs (@DrSGraff)

#Breastcancer #HER2 #resistance 📢 The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates 👉https://t.co/s2H2551oR6 @DrHBurstein @teamoncology @NBCCStopBC @DrSGraff @BreastDocUK @StoverLab @Debeblab (@cdrjournal)

Check this review 👇in #CBCjournal discussing the evolving landscape of therapies for HER2+ metastatic breast cancer including newly approved and emerging agents! #bcsm #HER2positive @YAbdouMD @DrSGraff @FengtingYan https://t.co/S1lghJWO7f (@CBCjournal)

Q3b: What did @AACR and @FDAOncology recently discuss in their latest episode of “Project Livin’ Label” about HER2-low breast cancer? @teamoncology @pre_ryan #HER2low #PathTwitter #BreastPath @israhkhan @Baskotacytopath @mkw_MD @KhouryThaer (@ASCP_Chicago)

ERBB2-Low (Also Known as HER2-Low) Breast Cancer ⁦@JAMAOnc⁩ ⁦@JAMA_current⁩ ⁦@JAMANetworkOpen⁩ https://t.co/ojYOnpK19e (@VivekSubbiah)

I had HER2 positive breast cancer and didn’t know it was the most common ! Am I right in thinking it’s more aggressive ? (@WendyHoban74)

What we learn when institutions combine their data. Great @carisls POA collaboration lead by @DrSGraff defining genomic profile & treatment responses of #HER2Low #breastcancer @myESMO #ESMO23 in 🇩🇪 @SylvesterCancer @chadinabhan (@Latinamd)

7P The standardized #HER2DX ERBB2 mRNA score predicts the clinical status of HER2 (positive, low and zero) in #breastcancer #precisiononcology #ESMOBreast23 (@RevealGenomics)

#ESMOBreast23 HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies 💥HER2DX may assist in the selection of neoadjuvant therapy in HER2-positive BC. Presented by Dr. Adrienne Waks @OncoAlert @myESMO (@dr_yakupergun)

Dr @hoperugo offers detailed analysis of safety & adverse events with T-DXd on Destiny Breast 04 in HER2 Low breast cancer. 🔑 key takeaway: tolerable safety signal similar to what we know from the treatment of HER2 positive breast cancer #ESMOBreast23 @OncoAlert (@DrSGraff)

In 2023, theres a case for just making some cisplatin and carboplatin for lung cancer, her2 positive breast cancer, and triple negative breast cancer. Id hate to have to find the drug to treat CNS mets that could have been cured if they had received optimal adjuvant therapy (@SyedMAhmedMDPhD)

Recently published in @JAMAOnc: Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. Congrats @adawaksmd @stolaney1 @EMittendorfMD and colleagues! #breastcancer #bcsm (@DFCI_BreastOnc)

HER2-low breast cancer had better survival outcomes compared to HER2 negative breast cancer in patients with early stage breast cancer https://t.co/O9gw4gnaOl (@MLPOncoData)

Great to hear of #ClinicalTrials like Determine in the UK: studying if licensed drugs, like one for HER2 breast cancer, could benefit another tumour type of w same driver. At #BTOG23 @MatthewGKrebs “Determine is needed to access drugs, when you can’t” https://t.co/4TXW4NvJfM (@Yvonne_Diaz_)